Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116202 | 0.98 | OPRM1 (0.37) | FAAHCNR1CNR2ALDH1A1OPRM1 | |
| SCHEMBL8072842 | 0.92 | CA2 (0.40) | CA2DNM1 | |
| SCHEMBL13619245 | 0.90 | CA2 (0.31) | CA2 | |
| SCHEMBL15508258 | 0.86 | TSHR (0.34) | CA2SPHK1 | |
| SCHEMBL2054509 | 0.84 | CA2 (0.33) | CA2 | |
| SCHEMBL14834118 | 0.82 | CA2 (0.36) | OPRM1CA2LMNADNM1 | |
| SCHEMBL31243817 | 0.82 | MAPK1 (0.49) | ALDH1A1LMNA | |
| SCHEMBL19054616 | 0.81 | CA2 (0.36) | CA2 | |
| SCHEMBL15508041 | 0.81 | — | — | |
| SCHEMBL16928574 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | claimed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | claimed |
| US-9643958-B2 | Deprotection method for protected hydroxyl group | ASAHI GLASS COMPANY, LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| EP-2700628-B1 | DEPROTECTION METHOD FOR PROTECTED HYDROXYL GROUP | ASAHI GLASS CO LTD (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-20140058113-A1 | DEPROTECTION METHOD FOR PROTECTED HYDROXYL GROUP | ASAHI GLASS COMPANY, LIMITED (JP) | 2014-02-27 | — | — | US | disclosed |
| EP-2700628-A1 | DEPROTECTION METHOD FOR PROTECTED HYDROXYL GROUP | Asahi Glass Company, Limited (JP) | 2014-02-26 | — | — | EP | disclosed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | disclosed |
| WO-1996012723-A1 | PROCESS FOR PREPARING ALKYLSILYL OR ARYLSILYL ETHERS | FMC CORPORATION (US) | 1996-05-02 | — | — | WO | disclosed |
| US-5493044-A | Process for preparing alkylsilyl or arylsilyl ethers | FMC CORPORATION (US) | 1996-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058113-A1 | DEPROTECTION METHOD FOR PROTECTED HYDROXYL GROUP | ADH1C, ADH1A, ADH5 | FAAH 539/4885CNR1 3170/4885CNR2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.